- Home
- LFVN vs ENGN Comparison
LFVN vs ENGN Comparison
Compare LFVN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFVN
- ENGN
- Stock Information
- Founded
- LFVN N/A
- ENGN 1999
- Country
- LFVN United States
- ENGN Canada
- Employees
- LFVN N/A
- ENGN N/A
- Industry
- LFVN Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- LFVN Health Care
- ENGN
- Exchange
- LFVN Nasdaq
- ENGN Nasdaq
- Market Cap
- LFVN 162.9M
- ENGN 191.1M
- IPO Year
- LFVN N/A
- ENGN N/A
- Fundamental
- Price
- LFVN $13.08
- ENGN $4.32
- Analyst Decision
- LFVN Strong Buy
- ENGN Buy
- Analyst Count
- LFVN 2
- ENGN 7
- Target Price
- LFVN $30.50
- ENGN $23.29
- AVG Volume (30 Days)
- LFVN 82.7K
- ENGN 102.1K
- Earning Date
- LFVN 09-04-2025
- ENGN 09-09-2025
- Dividend Yield
- LFVN 1.43%
- ENGN N/A
- EPS Growth
- LFVN 152.87
- ENGN N/A
- EPS
- LFVN 0.70
- ENGN N/A
- Revenue
- LFVN $222,347,000.00
- ENGN N/A
- Revenue This Year
- LFVN $17.36
- ENGN N/A
- Revenue Next Year
- LFVN $9.60
- ENGN N/A
- P/E Ratio
- LFVN $18.67
- ENGN N/A
- Revenue Growth
- LFVN 8.22
- ENGN N/A
- 52 Week Low
- LFVN $7.09
- ENGN $2.65
- 52 Week High
- LFVN $27.38
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- LFVN 48.87
- ENGN 70.93
- Support Level
- LFVN $12.07
- ENGN $3.52
- Resistance Level
- LFVN $14.08
- ENGN $3.89
- Average True Range (ATR)
- LFVN 0.70
- ENGN 0.27
- MACD
- LFVN -0.10
- ENGN 0.05
- Stochastic Oscillator
- LFVN 34.47
- ENGN 90.94
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.